Zacks Investment Research on MSN

Implied volatility surging for ANI Pharmaceuticals stock options

Investors in ANI Pharmaceuticals, Inc. ANIP need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 17, 2026 $55.00 Call had some of the highest ...
Nasdaq

ANI Pharmaceuticals Completes $17.25 Million Buyout of Royalty Obligation for ILUVIEN and YUTIQ

ANI Pharmaceuticals has paid $17.25 million to buy out royalty obligations for ILUVIEN and YUTIQ, enhancing financial flexibility. ANI Pharmaceuticals incurred a one-time payment of $17.25 million to ...
Hosted on MSN

ANI Pharmaceuticals (ANIP) stock trades down, here is why

Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) fell 3.3% in the morning session after investors appeared to take profits as the company announced strong preliminary 2025 ...
Seeking Alpha

ANI Pharmaceuticals: More Than Just A Generics Company

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue ...
Nasdaq

ANI Pharmaceuticals Launches Prucalopride Tablets Following FDA Approval

ANI Pharmaceuticals, Inc. announced the launch of its Prucalopride Tablets, a generic version of the drug Motegrity®, following final FDA approval of their Abbreviated New Drug Application. The new ...